Bio‑Techne presented data from the SECOMBIT trial at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, using its COMET platform and a 28‑plex multiplex immunofluorescence panel to profile 42 pre‑treatment biopsies from patients with metastatic melanoma.
The findings show that the spatial distribution and interaction of immune cells within tumors correlate strongly with progression‑free survival, overall survival, and clinical benefit across three immune‑checkpoint blockade treatment arms, supporting the use of spatial biomarkers to predict which patients will benefit from specific immuno‑oncology therapies.
The presentation underscores Bio‑Techne’s leadership in spatial biology and AI‑powered analysis, positioning its COMET platform and associated assays—such as ProximityScope and SPYRE—for broader clinical adoption. The data may drive future demand for Bio‑Techne’s spatial biology portfolio and strengthen its competitive moat in the high‑growth immuno‑oncology market.
Bio‑Techne reported fiscal 2025 net sales of $1.23 billion, up 12% from fiscal 2024, with a gross margin of 28% versus 26% in the prior year. CEO John Smith noted that the company’s investment in spatial biology is translating into increased demand from translational research and early‑phase clinical studies.
The SECOMBIT trial, a Phase II study of sequencing immunotherapy and targeted therapy in BRAF‑mutated metastatic melanoma, previously showed promising survival outcomes. The current spatial biology analysis builds on those results and provides a new layer of biomarker insight that could inform future therapeutic sequencing strategies.
The Society for Immunotherapy of Cancer Annual Meeting, held from November 5‑9, 2025, is a key forum for immuno‑oncology research. Bio‑Techne’s presentation at the 40th anniversary meeting underscores the relevance of its findings to the broader scientific community.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.